PTH
Invesco Dorsey Wright Healthcare Momentum ETF
The Invesco DWA Healthcare Momentum Portfolio tracks an index of U.S. healthcare firms selected and weighted by price momentum.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 283.5 M
ASSETS UNDER MGMT
74 bp
EXPENSES
Fund Basics
| Inception date | Oct 12, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GUARDANT HEALTH, INC. | 3.9 % |
| NATERA INC | 3.8 % |
| ROIVANT SCIENCES LTD. | 3.8 % |
| TENET HEALTHCARE CORP | 3.8 % |
| REVOLUTION MEDICINES, INC. | 3.6 % |
| INSMED INC | 3.6 % |
| 10X GENOMICS INC CLASS A | 3.4 % |
| TWIST BIOSCIENCE CORP. | 3.0 % |
| MEDPACE HOLDINGS, INC. | 2.9 % |
| IOVANCE BIOTHERAPEUTICS INC | 2.9 % |
Constituent Breakdown
| Number of holdings | 55 |
| Herfindahl-Hirschman Index | 240 |
| Wgt avg mkt cap (mns) | $13,158 |
| Large cap (>$10bn) | 43.0% |
| Mid cap ($2-10bn) | 43.1% |
| Small cap (<$2bn) | 13.0% |
| Developed mkts. | 99.9% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
| UNITED STATES | 95.0 % | |
| BRITAIN | 3.8 % | |
| NETHERLANDS | 1.1 % |
Historical Performance
Standardized Performance (as of 10/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 20.3% | 22.9% | 15.7% | 25.5% | 1.9% | 14.9% | 10.3% | 10.4% |
| Dividend Yield | 0.0% | 3.7% | 1.7% | 1.3% | 0.6% | 0.4% | 0.3% | 0.3% |
| Total Returns | 20.3% | 26.6% | 17.4% | 26.7% | 2.5% | 15.2% | 10.6% | 10.6% | Ann. Volatility | 27.9% | 27.1% | 27.0% | 26.1% | 26.1% | 27.5% | 24.9% | 24.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.07 | 25% |
| MSCI EAFE | 0.83 | 24% |
| MSCI Emg Mkts | 0.48 | 20% |
Liquidity Measures
| Avg. volume (000) | 32 |
| ADV traded (mns) | $2 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.21% |
Technical Indicators
| 30d moving avg. (EMA) | $59.05 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.31/-0.23 |
| Bollinger Bands (Upper/Lower) | $61.74/$56.22 |
| Short interest (% of AUM) | 1.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PTH |
Expenses vs. PTH |
ALTAR Score™ vs. PTH |
|---|---|---|---|---|
| HLTH | Tema Healthcare AI ETF | 28.6% | -74 bp | +1.7% |
| FMED | Fidelity Disruptive Medicine ETF | 26.7% | -24 bp | +0.4% |
| HELX | Franklin Genomic Advancements ETF | 24.3% | -24 bp | +0.4% |
| WDNA | WisdomTree BioRevolution Fund | 23.8% | -29 bp | +0.8% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 22.6% | -39 bp | -0.7% |
| ARKG | ARK Genomic Revolution ETF | 22.6% | +1 bp | +0.3% |
| XBI | State Street SPDR S&P Biotech ETF | 22.4% | -39 bp | -1.1% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 22.1% | -9 bp | +1.5% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 20.7% | -14 bp | +1.0% |
| GNOM | Global X Genomics & Biotechnology ETF | 20.0% | -24 bp | -0.6% |
Risk and Returns: PTH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/16/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.7%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,440 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. PTH's ALTAR Score™ is approximately -3.6 standard
deviations above the category average. This places PTH in the 1st percentile
among funds in the category.
Sell-Side Consensus
$74.02
PRICE TARGET
+29.1%
UPSIDE